SynthesisWorld journal of gastroenterology2011
TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis.
Synthesis in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Meta-analysis shows significant association of the TP53 Arg72Pro with ovarian cancer risk.Molecular biology reports · 2012Pooled it
- Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma.Frontiers in oncology · 2018Article
- Modeling gene-environment interactions in oral cavity and esophageal cancers demonstrates a role for the p53 R72P polymorphism in modulating susceptibility.Molecular carcinogenesis · 2014Article
- The determination of genetic markers of age-related cancer pathologies in populations from Kazakhstan.Frontiers in genetics · 2013Article
- p53 Codon 72 arginine/proline polymorphism and cancer in Sudan.Molecular biology reports · 2012Article
- Alterations of the TP53 gene in gastric and esophageal carcinogenesis.Journal of biomedicine & biotechnology · 2012Review
- TP53 gene polymorphism: importance to cancer, ethnicity and birth weight in a Brazilian cohort.Journal of biosciences · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
aimTo investigate the association between TP53 Arg72Pro polymorphism and esophageal cancer (EC) risk using meta-analysis.
methodsAll eligible studies published before March 1, 2010 were selected by searching PubMed using keywords "p53" or "TP53", "polymorphism" or "variation", "esophageal" and "cancer" or "carcinoma". Crude odds ratios (ORs) with 95% confidence intervals (CIs) were assessed for EC risk associated with TP53 Arg72Pro polymorphism using fixed- and random-effects models.
resultsNine case-control studies involving 5545 subjects were included in this meta-analysis. Significantly reduced risk of EC was associated with TP53 genotypes for Arg/Arg + Arg/Pro vs Pro/Pro (OR = 0.73, 95% CI: 0.57-0.94, P = 0.014). Subgroup analyses according to the source of controls and the specimens used for determining TP53 Arg72Pro genotypes or sample size showed that significantly reduced risk was observed only in studies which have population-based controls (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.66, P < 0.001), and use white blood cells or normal tissue to assess TP53 genotypes of cases (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001) or include at least 200 subjects (Arg/Arg vs Pro/Pro: OR = 0.56, 95% CI: 0.47-0.65, P < 0.001). Analysis restricted to well-designed studies also supported the significantly decreased risk of EC (Arg/Arg vs Pro/Pro: OR = 0.54, 95% CI: 0.46-0.64, P < 0.001).
conclusionTP53 Arg72 carriers are significantly associated with decreased EC risk. Nevertheless, more well-designed studies are needed to confirm our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.